Population seroconversion across the measles two-dose schedule
Every child starts with zero measles-specific antibody protection.
Maternal antibodies cross the placenta before birth.
They fade within the first year of life.
A short immunity gap follows before vaccination.
One infected person can infect 12 to 18 others.
The virus lingers airborne in a room for hours.
Unvaccinated pockets ignite fast local outbreaks.
Measles needs about 95% population immunity to stop spreading.
A single dose alone leaves gaps in coverage.
Health agencies added a routine second dose.
The schedule now targets near-complete population protection.
About 93% of children develop protective antibodies after dose one.
Earlier doses meet lingering maternal antibody interference.
12 to 15 months maximizes reliable seroconversion.
Delaying further raises exposure risk needlessly.
A weakened measles virus mimics natural infection.
The immune system builds memory B cells and antibodies.
Protection typically appears within two to three weeks.
A 7% gap remains after just one dose.
That gap can still sustain local outbreaks.
A second dose was added to close it.
One dose protects most children but leaves real outbreak risk.
Roughly 7% of children fail to seroconvert after their first dose.
Leftover maternal antibodies can neutralize the vaccine strain.
Younger age at dosing raises this risk slightly.
Cold-chain handling issues can also reduce potency.
These children look and act completely normal.
No symptom distinguishes them from protected peers.
Only serology reveals the missing antibody response.
Seven percent sounds small but scales into thousands per cohort.
A second dose is not a simple booster.
For non-responders, it functions as a first true dose.
Most of this group finally seroconverts then.
The second dose captures most children who missed dose one.
Most first-dose non-responders finally build antibodies now.
Maternal antibody interference is long gone by this age.
The immune system responds far more reliably.
Children already protected get a titer boost too.
Higher, longer-lasting antibody levels result.
This adds durability across childhood and beyond.
A tiny fraction still does not seroconvert.
This is true secondary vaccine failure.
High two-dose coverage still keeps communities safe.
School-entry requirements make dose two a population safety net.
Two doses push measles protection above 97% of the population.
One dose alone leaves meaningful outbreak risk.
Two doses close most of that remaining gap.
Population-level protection becomes durable and reliable.
High two-dose coverage approaches herd immunity thresholds.
Infants too young for vaccination gain indirect protection.
Immunocompromised people also benefit from reduced circulation.
High coverage protects those who cannot be vaccinated themselves.
Local pockets of under-vaccination remain vulnerable.
Imported cases can spark clusters there quickly.
Sustained high coverage is the durable defense.